Ribociclib
HER2-negative Circulating Tumor Cells
Prof. Wolfgang JanniSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the HER2-negative Circulating Tumor Cells cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eribulin Prof. Wolfgang Janni | Phase 2 | B |
FULVESTRANT Prof. Wolfgang Janni | Phase 2 | B |
LEUPROLIDE Prof. Wolfgang Janni | Phase 2 | B |
Zoladex Prof. Wolfgang Janni | Phase 2 | B |
Letrozole Prof. Wolfgang Janni | Phase 2 | B |
Same molecule, other indications
Ribociclib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →